Cargando…

Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England

BACKGROUND: The coronavirus pandemic resulted in many changes which had the potential to impact mortality related to opioid agonist therapy (OAT; methadone, buprenorphine), including changes in the prescribing and dispensing of OAT and patterns of drug availability and use. We aimed to assess the im...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldabergenov, D, Reynolds, L, Scott, J, Kelleher, MJ, Strang, J, Copeland, CS, Kalk, NJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531664/
https://www.ncbi.nlm.nih.gov/pubmed/36265326
http://dx.doi.org/10.1016/j.drugpo.2022.103877
_version_ 1784801948364439552
author Aldabergenov, D
Reynolds, L
Scott, J
Kelleher, MJ
Strang, J
Copeland, CS
Kalk, NJ
author_facet Aldabergenov, D
Reynolds, L
Scott, J
Kelleher, MJ
Strang, J
Copeland, CS
Kalk, NJ
author_sort Aldabergenov, D
collection PubMed
description BACKGROUND: The coronavirus pandemic resulted in many changes which had the potential to impact mortality related to opioid agonist therapy (OAT; methadone, buprenorphine), including changes in the prescribing and dispensing of OAT and patterns of drug availability and use. We aimed to assess the impact of the first lockdown (initiated March 23rd 2020) on methadone- and buprenorphine-related deaths in England in people both prescribed and not prescribed OAT using data from the National Programme on Substance Abuse Deaths. METHODS: This was a retrospective post-mortem toxicology study of OAT-related deaths which occurred in the 3-month period March 23rd to June 22nd in the years 2016-2020. Provisional data regarding numbers accessing treatment for opioid use disorder was provided by the National Drug Treatment Monitoring System. RESULTS: We found a 64% increase in methadone-related deaths in March to June 2020 compared to March to June 2019 (2019 n = 96; 2020 projected n = 157). There were increases in the mortality rate of both in-treatment decedents (22% increase; 2019 n = 45; an exponential smoothing model of the 2016-19 trend [α=0.5] predicted 44 deaths in 2020, 55 were reported) and decedents not prescribed methadone (74% increase; 2019 n = 46; 2016-19 trend predicted 43 deaths in 2020, 80 were reported). There was no increase in buprenorphine-related deaths (2019 n = 9/529; 2020 n = 11/566). There were no changes in the numbers of deaths where other opioids or multiple substances were detected, or in methadone levels detected. Numbers of people accessing treatment for opioid use disorder in 2020 did not decrease relative to previous years (p >0.05). CONCLUSIONS: Methadone-related deaths in non-prescribed individuals, but not prescribed individuals, increased considerably above the annual trend forecast for 2020 during the first COVID-19 lockdown in England. Further studies are thus needed to understand this difference.
format Online
Article
Text
id pubmed-9531664
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-95316642022-10-05 Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England Aldabergenov, D Reynolds, L Scott, J Kelleher, MJ Strang, J Copeland, CS Kalk, NJ Int J Drug Policy Research Paper BACKGROUND: The coronavirus pandemic resulted in many changes which had the potential to impact mortality related to opioid agonist therapy (OAT; methadone, buprenorphine), including changes in the prescribing and dispensing of OAT and patterns of drug availability and use. We aimed to assess the impact of the first lockdown (initiated March 23rd 2020) on methadone- and buprenorphine-related deaths in England in people both prescribed and not prescribed OAT using data from the National Programme on Substance Abuse Deaths. METHODS: This was a retrospective post-mortem toxicology study of OAT-related deaths which occurred in the 3-month period March 23rd to June 22nd in the years 2016-2020. Provisional data regarding numbers accessing treatment for opioid use disorder was provided by the National Drug Treatment Monitoring System. RESULTS: We found a 64% increase in methadone-related deaths in March to June 2020 compared to March to June 2019 (2019 n = 96; 2020 projected n = 157). There were increases in the mortality rate of both in-treatment decedents (22% increase; 2019 n = 45; an exponential smoothing model of the 2016-19 trend [α=0.5] predicted 44 deaths in 2020, 55 were reported) and decedents not prescribed methadone (74% increase; 2019 n = 46; 2016-19 trend predicted 43 deaths in 2020, 80 were reported). There was no increase in buprenorphine-related deaths (2019 n = 9/529; 2020 n = 11/566). There were no changes in the numbers of deaths where other opioids or multiple substances were detected, or in methadone levels detected. Numbers of people accessing treatment for opioid use disorder in 2020 did not decrease relative to previous years (p >0.05). CONCLUSIONS: Methadone-related deaths in non-prescribed individuals, but not prescribed individuals, increased considerably above the annual trend forecast for 2020 during the first COVID-19 lockdown in England. Further studies are thus needed to understand this difference. The Authors. Published by Elsevier B.V. 2022-12 2022-10-04 /pmc/articles/PMC9531664/ /pubmed/36265326 http://dx.doi.org/10.1016/j.drugpo.2022.103877 Text en © 2022 The Authors. Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Research Paper
Aldabergenov, D
Reynolds, L
Scott, J
Kelleher, MJ
Strang, J
Copeland, CS
Kalk, NJ
Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England
title Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England
title_full Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England
title_fullStr Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England
title_full_unstemmed Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England
title_short Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England
title_sort methadone and buprenorphine-related deaths among people prescribed and not prescribed opioid agonist therapy during the covid-19 pandemic in england
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531664/
https://www.ncbi.nlm.nih.gov/pubmed/36265326
http://dx.doi.org/10.1016/j.drugpo.2022.103877
work_keys_str_mv AT aldabergenovd methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland
AT reynoldsl methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland
AT scottj methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland
AT kellehermj methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland
AT strangj methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland
AT copelandcs methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland
AT kalknj methadoneandbuprenorphinerelateddeathsamongpeopleprescribedandnotprescribedopioidagonisttherapyduringthecovid19pandemicinengland